Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Learn more about HealthTree
New Maintenance Strategies for Newly Diagnosed Myeloma Patients With Ashraf Badros, MD, University of Maryland image

New Maintenance Strategies for Newly Diagnosed Myeloma Patients With Ashraf Badros, MD, University of Maryland

Posted on: Oct 21, 2022
Play Episode
Also available on
play podcast in spotifySpotify play podcast in apple podcastsApple Podcasts play podcast in youtubeYoutube
Description

Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses? 

Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive. 

Myeloma experts are working to identify more personalized approaches for each type of myeloma patient. We know that patients who are still MRD positive following high dose therapy are more likely to have shorter remissions and the use of a different maintenance therapy may help patients who aren't getting their deepest responses do better over time. 

Thanks to our episode sponsor, Takeda Oncology

User uploaded media

Overview

Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses? 

Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive. 

Myeloma experts are working to identify more personalized approaches for each type of myeloma patient. We know that patients who are still MRD positive following high dose therapy are more likely to have shorter remissions and the use of a different maintenance therapy may help patients who aren't getting their deepest responses do better over time. 

Thanks to our episode sponsor, Takeda Oncology

User uploaded media

On this episode
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Ashraf Badros, MD

Ashraf Badros, MD

Ashraf Badros, MD, is a Professor and Director of the Multiple Myeloma Service at the Greenebaum Cancer Center of the University of Maryland School of Medicine. He has extensive clinical experience in the diagnosis and management of multiple myeloma. Prior to joining the University of Maryland, he was a faculty member of the Myeloma Institute for Research and Therapy at the University of Arkansas. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts. Dr. Badros is involved in the development of targeted novel therapeutics. Dr. Badros’s clinical research focuses on novel agents and manipulation of the immune system to enhance antimyeloma effects of various therapies. He was involved in the initial clinical trials of thalidomide, lenalidomide and proteasome inhibitors including bortezomib and carfilzomib. He has conducted seminal trials in transplantation for patients with renal failure, several trials for relapsed and refractory multiple myeloma focusing on novel agents, and defined risk factors of osteonecrosis of the jaw in multiple myeloma patients and had a NIH-funded grant to investigate its pathogenesis. Dr. Badros is a member of International Myeloma Working Group. He has written or cowritten more than 100 publications in peer-reviewed journals including the New England Journal of Medicine, Blood, Leukemia, Nature Medicine, the British Journal of Haematology, Transfusion, the Journal of Clinical Oncology, and the American Journal of Medicine as well as five chapters in medical texts. He served a fellowship in oncology at Georgetown University, Washington, DC, completed an internship and residency at Harbor Hospital, Baltimore, MD and earned his medical degree from Ain Shams University, Cairo, Egypt.
Transcript

Related Content